^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report
Published date:
01/29/2021
Excerpt:
...the patient was diagnosed with late-stage lung adenocarcinoma with MET exon14 skipping gene mutation….Crizotinib was administered (250 mg bid) for 8 months, and her disease achieved partial regression (PR) and progression-free survival (PFS), which lasted for 8 months. The patient also reached PR after the second-line treatment with cabozantinib, and is currently under follow-up, with an overall survival (OS) of >12 months.
DOI:
10.1097/MD.0000000000024300
Source:
Title:
Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma
Excerpt:
Off-label crizotinib 250mg twice daily was commenced and associated with improvement in cardio-pulmonary symptoms within a week of use….The current report not only supports that MET exon 14 skipping mutated lung adenocarcinomas are oncogene addicted to MET but also discloses that rapid clinical/radiographic responses can be seen with use of the approved MET TKI crizotinib...
DOI:
10.1016/j.jtho.2016.01.017
Source:
Title:
Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation
Excerpt:
This is the first report to our knowledge that associates clinical response to crizotinib with MET splice site mutation in lung adenocarcinoma….Although difficult to separate response of his lung mass from continued effects of palliative radiation, we observed a clear decrease in size of the unirradiated adrenal lesion from which the MET splice site mutation was identified.
DOI:
10.1016/j.cllc.2015.01.009
